

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/696,717
				Filing Date	October 29, 2003
				First Named Inventor	Wylie Vale
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	AO-CLFR:194USD1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
EGS	AA	US-4,864,019	09/1989	Vale et al.	
	AB	US-5,102,868	04/1992	Woodruff et al.	
	AC	US-5,428,011	06/1995	Sheth et al.	
	AD	US-5,786,179	07/1998	Kousoulas et al.	
	AE	US-5,830,671	11/1998	Dennis et al.	
	AF	US-6,060,460	05/2000	Ferguson	


FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
EGS	BA	WO-9510610	04-20-1995	Jolla Cancer Res Foundation	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
EGS	CA	Brown et al., Science, March 1999, Vol. 283, pgs 2080-2082.		
	CB	Alberts et al, Molecular Biology of the Cell, 2nd Edition, 1989, pg 552.		
	CC	Lewis, K. et al, "Betaglycan Binds Inhibin and Can Mediate Functional Antagonism of Activin Signalling," Nature Vol. 404, 2000, pgs 411-414.		
	CD	Chong et al, "Immunocytochemical Localization of Latent Transforming Growth Factor-β1 Activation by Stimulated Macrophages," Journal of Cellular Physiology Vol. 178, 1999, pgs 275 - 283.		
	CE	DePaolo et al, "Inhibins, Activins, and Follistatins: The Saga Continues," P.S.E.B.M. Vol. 214, 1997, pgs 328 - 339.		
	CF	Chong et al, "Structure and Expression of a Membrane Component of the Inhibin Receptor System," Endocrinology Vol. 141, 2000, pgs 2600 - 2607.		
	CG	Kaname et al, "Betaglycan has Multiple Binding Sites for transforming Growth Factor-β1," Biochemical Journal Vol. 315, 1996, pgs 815 - 820.		
	CH	Draper et al, "Identification of an Inhibin Receptor in Gonadal Tumors from inhibit α-Subunit knockout Mice," The Journal of Biological Chemistry Vol. 273, 1998, pgs 398 - 403.		
	CI	Massague, J., "TGF-Beta Signal Transduction," Annu Rev Biochem Vol. 67, 1998, pgs 753 - 791.		
	CJ	Massague et al, "Cellular Receptors for Type Beta Transforming Growth Factor, J. Biol Chem Vol. 260, 1985, pgs 2636 - 2645.		
	CK	Lopez-Casillas et al, "Structure and Expression of the Membrane Proteoglycan Betaglycan, a Component of the TGF-beta Receptor System," Cell Vol. 67, 1991, pgs 785 - 795.		
	CL	Wang et al, "Expression Cloning and Characterization of the TGF-beta Type III Receptor," Cell Vol. 67, pgs 797-805.		

Examiner Signature	/Elly Gerald Stoica/	Date Considered	11/03/2006
--------------------	----------------------	-----------------	------------



PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete If Known	
				Application Number	10/696,717
				Filing Date	October 29, 2003
				First Named Inventor	Wylie Vale
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	AO-CLFR:194USD1

EGS	CM	Derynck et al, "TGF-Beta Receptor Signaling," Biochim Biophys Acta Vol. 1333, pgs F105 - 50.	
	CN	Lopez-Casillas et al, "Betaglycan can Act as a Dual Modulator of TGF-Beta Access to Signaling Receptors: Mapping of Ligand Binding and GAG Attachment Sites," J Cell Biol Vol. 124, pgs. 557-568.	
	CO	Sun et al, "Expression of Transforming Growth Factor Beta Type III receptor Suppresses Tumorigenicity of Human Breast Cancer MDA-MB-231 Cells," J. Biol Chem Vol. 272, 1997, pgs 25367 - 25372.	
	CP	Chen et al, "Expression of Transforming Growth Factor Beta (TGFbeta) type III Receptor Restores Autocrine TGFbeta1 Activity in Human Breast Cancer MCF-7 Cells," J Biol Chem Vol. 272, 1997, pgs 12862 - 12867.	
	CQ	Brown et al, "Requirement of Type III TGF-Beta Receptor for Endocardial Cell Transformation in the Heart," Science Vol. 283, pgs 2080-2082.	
↓	CR	LeBrun et al, "Activin and Inhibin have Antagonistic Effects on Ligand-Dependant Heteromerization of the Type I and Type II Activin Receptors and Human Erythroid Differentiation," Molecular and Cellular Biology Vol. 17, no. 3, March 1997, pgs 1682 - 1691.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Elly Gerald Stoica/	Date Considered	11/03/2006
-----------------------	----------------------	--------------------	------------